Telbivudine + Enecavir + Adefovir
ApprovedUNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HBV-related Liver Cirrhosis
Conditions
HBV-related Liver Cirrhosis
Trial Timeline
Feb 1, 2013 → Mar 1, 2015
NCT ID
NCT01799486About Telbivudine + Enecavir + Adefovir
Telbivudine + Enecavir + Adefovir is a approved stage product being developed by Novartis for HBV-related Liver Cirrhosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT01799486. Target conditions include HBV-related Liver Cirrhosis.
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01799486 | Approved | UNKNOWN |